Peter Kufer,Dirk Nagorsen,Juergen Scheele,Gerhard Zugmaier,Matthias Klinger,Patrick Hoffmann,Virginie Naegele,Elaine-Pashupati Dopfer
申请号：
US15604341
公开号：
US20170327581A1
申请日:
2017.05.24
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
